Clinical Trials Directory

Trials / Unknown

UnknownNCT02895646

Genomic Study of Genetic Polymorphisms Involved in Immediate Allergic Reactions to Beta-lactam Antibiotics

Status
Unknown
Phase
Study type
Observational
Enrollment
2,356 (actual)
Sponsor
Central Hospital, Nancy, France · Academic / Other
Sex
All
Age
Healthy volunteers
Accepted

Summary

Beta-lactam antibiotics include penicillin and cephalosporins and are among the most prescribed antibiotics. This category of drugs is the most involved in immediate allergic manifestations with 2% reactions in treated subjects and a fatal outcome in 1/50000 treatments. Reactions are IgE-mediated and have a considerable but unknown genetic origin, revealed by studies in groups of different ethnical origins in the same geographical region. There are also some families with a high frequency of allergic reactions without identified Mendelian inheritance. The purpose of this study is to identify predictive risk factors associated to immediate allergic reactions against beta-lactam antibiotics with a pangenomic approach. A secondary purpose is to identify rare predictive factors with homozygosity mapping and exome sequencing in various families with high risk of allergy to beta-lactam antibiotics.

Conditions

Interventions

TypeNameDescription
OTHERCollection of blood sample

Timeline

Start date
2012-06-01
Primary completion
2017-06-01
Completion
2017-06-01
First posted
2016-09-12
Last updated
2017-02-03

Source: ClinicalTrials.gov record NCT02895646. Inclusion in this directory is not an endorsement.

Genomic Study of Genetic Polymorphisms Involved in Immediate Allergic Reactions to Beta-lactam Antibiotics (NCT02895646) · Clinical Trials Directory